Skip to main content
MUSTANG BIO, INC. logo

MUSTANG BIO, INC. — Investor Relations & Filings

Ticker · MBIO ISIN · US62818Q1040 LEI · 5493004W0VC1DPECQ779 US Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2018-11-14 Regulatory Filings
Country US United States of America
Listing US MBIO

About MUSTANG BIO, INC.

https://www.mustangbio.com/

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies. The company's primary focus is on translating medical breakthroughs into potential cures for difficult-to-treat cancers and rare genetic diseases. Its pipeline is centered on Chimeric Antigen Receptor (CAR) T-cell therapies, a form of immunotherapy. Mustang Bio's strategy involves in-licensing promising technologies from academic institutions and advancing them through clinical trials, supported by its in-house manufacturing capabilities to ensure the production and delivery of these advanced treatments.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions that the company issued a press release providing a corporate update and announcing financial results for the third quarter ended September 30, 2018. The document itself does not contain detailed financial statements or substantive financial data but rather references a press release as an exhibit. The length of the document is only 2973 characters, which is quite short and consistent with an announcement rather than a full financial report. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not contain the full financial report or detailed analysis itself.
2018-11-14 English
FORM 10-Q
Interim / Quarterly Report 9M 2018
2018-11-13 English
FORM 4
Director's Dealing
2018-11-13 English
FORM 4
Director's Dealing
2018-11-06 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions Item 2.02, "Results of Operations and Financial Condition," and states that the company issued a press release announcing financial results for the second quarter ended June 30, 2018. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes the press release as an exhibit. The length of the document is 2922 characters, which is relatively short and consistent with an announcement rather than a full financial report. According to the rules, a document that announces financial results via a press release and does not contain the full financial data should be classified as an Earnings Release (ER).
2018-08-13 English
FORM 10-Q
Interim / Quarterly Report Q2 2018
2018-08-13 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.